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yslipidemia and hypertension are 
Drecognized as prominent risk factors in the development of cardiovascular 
disease (CVD).  Studies have consistently 
i n d i c a t e d  t h a t  h y p e r t e n s i o n  a n d 
hypercholesterolemia frequently coexist, causing 
1 what is known as dyslipidaemia in hypertension.
It is known that lipids play a pivotal role in the 
development of atherosclerosis starting from 
initial changes. Oxidized-LDL, is particularly 
atherogenic and has been suggested to affect 
endothelium-dependent vascular tone through a 
decreased biological activity of endothelium-
2,3
derived nitric oxide (NO).  Hypertension equally 
affects endothelial function, thus when these two 
conditions coexist, the endothelium is not spared 
and the individual is at a greater risk for 
atherosclerosis.
The prevalence of dyslipidemia as seen among 
patients with hypertension vary from region to 
region. In a study on abdominal adiposity and 
atherogenic dyslipidaemia among geriatric 
Nigerians, dyslipidaemic hypertensive patients 
4
constituted 44.3%  of their study population. And 
among newly diagnosed hypertensive patients, a 
5 6prevalence of 58.9% was reported. Another study  
in the South-West Nigeria also reported a positive 
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INTRODUCTION: The coexistence of dyslipidaemia and hypertension results in enhanced atherosclerosis. 
Adequate treatment of dyslipidaemia in hypertensive patients is thus essential for reducing the burden of 
cardiovascular diseases.
OBJECTIVE: To determine the prevalence of dyslipidaemia among hypertensives and evaluate lipid treatment 
status of patients with dyslipidaemia in a tertiary hospital in Nigeria.
METHODS: This cross-sectional comparative study was done between May, 2015 and June, 2016 in a tertiary 
hospital in Nigeria. The serum lipid levels of adult patients with hypertension and controls without 
hypertension were determined. Lipid treatment status of patients with dyslipidaemia were also reviewed. 
Serum lipid levels were analyzed using spectrophotometric methods.
RESULTS: The study included 200 adult hypertensive patients and 100 control participants. The mean age (SD) 
was 56.3 (6.9) years and 54.9 (8.3) years with range 41-68 and 44-69 years for patients and controls 
respectively. Eighty-eight (44.0%) hypertensive patients and 23(23.5%) of the control group were found to have 
dyslipidaemia. Out of the 60(68.2%) patients with elevated LDL-C, 32(53.3%) had LDL-C >4.1mmol/L, out of 
which only 8(25%) were on antilipid medication. 
CONCLUSION: Over one-third of studied hypertensive patients had dyslipidaemia and only a quarter of those 
who needed antilipids were on the medication. Greater awareness is needed both in the medical and patient 
communities in order to effectively manage dyslipidaemic hypertension, and hence aid in ameliorating the 
burden of cardiovascular diseases.
Correspondence to: Ijeoma A. Meka. 
Department of Chemical Pathology, College of Medicine,
University of Nigeria Enugu Campus, Enugu State, Nigeria.
Email: ijeamaka20@gmail.com , ijeoma.meka@unn.edu.ng
Phone: +234 703 096 7673
c o r r e l a t i o n  b e t w e e n  h y p e r t e n s i o n  a n d 
hyperlipidaemia. In the United States, the 
prevalence has been estimated to range from 15 to 
7  
31% and estimated to be inherent in over 5 million 
8Turkish adults.  Globally, raised cholesterol is 
estimated to cause 2.6 million deaths and 29.7 
9million disability adjusted life years.
Cardiovascular disease, the primary clinical 
outcome of dyslipidaemia among hypertensive s is 
no longer merely an emerging problem in Africa, 
and while the risk factors and the pattern of 
diseases causing CVD may differ from those in 
Europe and North America, the impact is greater 
10
in Africa.  Age-specic mortality and morbidity 
associated with CVD and chronic diseases are 
higher in sub-Saharan Africa than in established 
11market economies.
Several medications exist for the treatment of 
dyslipidemia. Among these are the HMG-CoA 
reductase inhibitors (statins), brates, bile acid 
sequestrants, lipoprotein lipase inhibitors and 
cholesterol  absorption inhibitors .  These 
medications either exist singly or in combination.
Though both Eighth Joint National Committee 
12(JNC 8)  and the National Cholesterol Education 
Program's series of Adult Treatment Panel (NCEP 
13 ATP) reports have been developed to provide 
healthcare professionals with recommendations 
p e r t i n e n t  t o  d e t e c t i n g  a n d  m a n a g i n g 
dyslipidemia, it has been reported that the quality 
of care for dyslipidemia is still suboptimal in 
 14
general.  The consequences of under treatment (or 
no  t reatment)  contr ibutes  to  the  r i s ing 
cardiovascular disease burden. 
The aim of this study is to contribute to existing 
data on the prevalence of dyslipidaemia among 
hypertensive patients receiving treatment and to 
determine the level of lipid treatment among 
dyslipidaemic hypertensive patients in the study 
setting in order to highlight the unmet need for 
lipid control in our patients. 
MATERIALS AND METHODS
Study design and location
This cross-sectional comparative study was 
carried out at University of Nigeria Teaching 
Hospital (UNTH), Enugu, Nigeria, between May, 
2015 and June, 2016. UNTH, Enugu is the pioneer 
teaching hospital in the Southeastern Nigeria and 
is owned by the Federal government of Nigeria. It 
is currently located at Ituku-Ozalla, at the outskirt 
of Enugu city and majorly serves about 5 states in 
its vicinity.
Study Population
Study participants included patients with essential 
hypertension attending medical out-patient clinic 
at the University of Nigeria Teaching Hospital. A 
total of 200 adult hypertensive patients aged 18 
years and above who have been on treatment for at 
least 3 months were recruited using systematic 
sampling. This was done using a sampling interval 
of 2, thus the rst patient who presented at the 
rd thclinic was selected, followed by the 3 , 5 , till 
sample size was completed. Patients with 
secondary hypertension, pregnant women and 
those declining consent were excluded from the 
study. Also, another age and sex matched 100 
control participants without hypertension were 
recruited from hospital staff and patients' relatives 
for the study. Individuals on oral contraceptives, 
antipsychotics, anticonvulsants, steroids and other 
medications that might affect lipid levels were also 
excluded.
Denition of Hypertension and Dyslipidaemia
Blood pressure readings were based on the JNC 
VII classication and guidelines. Normal blood 
pressure was dened as a systolic blood pressure 
of <120 mmHg and a diastolic blood pressure of < 
80 mmHg.
Dyslipidaemia was dened using the National 
Cholesterol Education Program Adult Treatment 
13panel III (NCEP-ATP III)  criteria as follows: Total 
Cholesterol (TC) > 5.2 mmol/L, Low Density 
Lipoprotein-cholesterol (LDL) > 3.4 mmol/L, 
Triglycerides (TG) > 1.7 mmol/L and High 
Density l ipoprotein-cholesterol  (HDL) < 
1.0mmol/L.
NCEP-ATP III also identied other risk factors for 
the development of coronary heart disease (CHD) 
which includes Hypertension, Cigarette smoking, 
Diabetes, Age Male > 45 years, Female > 55 years, 
family history of premature CHD, Obesity
Sample collection and analysis
After at least a ten minutes rest, blood pressure was 
measured twice with 5 minutes interval, using a 
sphygmomanometer (Omron, Japan). This was 
done on the left hand while sitting, and the mean of 
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the two readings of the systolic and diastolic 
pressures recorded. Blood samples (5mls) were 
collected aseptically after 10 -14 hours of fasting 
into lithium heparin bottles, centrifuged for 10 
minutes at 1500 rpm and plasma separated into 
o
plain tubes. These were stored at -18 C and 
analyzed a day after collection. Total cholesterol 
was measured using Enzymatic Endpoint (CHOD-
15
PAP) method  (Randox, UK). Triglycerides were 
16 measured using the GPO-PAP method (Randox, 
UK). 
High density lipoprotein-cholesterol (HDL-C) was 
17 measured using the precipitation technique
(Randox,UK) while Low density lipoprotein-
cholesterol (LDL-C) was calculated using the 
 18
Friedewald equation.   Friedewald equation was 
not used for patients with plasma triglyceride 
concentration greater than 400mg/dL (4.52 
mmol/L). Quality control was ensured by the use 
of commercially prepared quality control 
materials (Levels 1 and 3) included in every batch 
of samples analyzed. Inter-assay and intra-assay 
Coefcient of variation were recorded as shown in 
Table 6.  
D a t a  r e g a r d i n g  d u r a t i o n  o f  t r e a t m e n t , 
antihypertensive and lipid lowering medications, 
age, sex and race were also collected from the 
participants.
Ethical considerations
Informed consent was obtained from participants 
after the purpose of the study was explained to 
them. Ethical clearance was obtained from UNTH 
Health Research and Ethics Committee.
Statistical analysis
Data was double-entered into a Microsoft Excel 
spreadsheet and analysis was carried out using Epi 
Info 3.5.1(CDC, Atlanta, GA, USA). Continuous 
variables were summarized as means (standard 
deviation [SD]), number and percentages while 
Categorical variables were presented only as 
proportions (number) and percentages. Student's 
t-test was used to compare continuous variables 
and chi square used for categorical values. All tests 
were two-tailed with p < 0.05 taken as statistically 
signicant. 
RESULTS
Two hundred (200) adult hypertensive patients 
and 100 controls without hypertension were 
included in the study. All patients and controls 
were 40 years and above and of Igbo tribe. The 
mean (SD) age was 56.3 (6.9) years and 54.9 (8.3) 
years with range 41-68 and 44-69 years for patients 
and controls respectively.  There were 64 male and 
136 female patients; while controls consisted of 40 
males and 60 females. Male to female ratio was 1:2 
and 1:1.5 for patients and controls respectively. 
Based on ATP III criteria, a statistically greater 
number of hypertensive patients 88 (44.0%) were 
found to have dyslipidaemia when compared to 
the control group (P = 0.0004). Out of the 88 
patients with dyslipidaemia, 60 (68.2%) had 
elevated LDL-cholesterol >3.4 mmol/L, 44(50.0%) 
had elevated Total Cholesterol >5.2mmol/L, 8 
(9.1%) had elevated triglygerides >1.7mmol/L and 
44(50.0%) had reduced HDL-cholesterol levels less 
than 1.0mmol/L. Out of the 60 (68.2%) with 
elevated LDL-cholesterol, 32 (53.3%) had LDL-C 
>4.1mmol/L. 
Among the control group, 23 (23.0%) had 
dyslipidaemia. Out of the 23 controls with 
dyslipidaemia, 10(43.5%) had elevated LDL-
cholesterol >3.4 mmol/L, 14(60.9%) had elevated 
Total Cholesterol >5.2mmol/L, 3(13.0%) had 
elevated triglygerides >1.7mmol/L and 10(43.5%) 
had reduced HDL-cholesterol levels less than 
1.0mmol/L. None had elevated LDL-cholesterol 
>4.1mmol/L. 
 A signicantly greater proportion of females 
81(41.3%) had dyslipidaemia when compared 
with 30(28.8%) of males, P=0.03. Among the 
hypertensive group, 64(47.0%) of the females and 
24(37.5%) of the males had dyslipidaemia, whereas 
in the control group, 17(28.3%) of the females and 
6(15.0%) of the males had dyslipidaemia. This 
gender distribution is shown in Figure 1.
 Hypertensives  with dysl ipidaemia had 
signicantly higher mean values of total- and LDL-
cholesterol with lower value of HDL-cholesterol 
when compared with hypertensives without 
dyslipidaemia as shown in Table 2. This pattern 
was also seen when comparing hypertensives with 
d y s l i p i d a e m i a  w i t h  c o n t r o l s  w i t h o u t 
dyslipidaemia (Table 4), but among control 
subjects ,  the values in individuals with 
dyslipidaemia were higher but not signicant 
(Table 3). Differences in triglyceride levels were 
however signicant among controls but not 
among hypertensive patients.
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W h e n  c o m p a r e d  w i t h  c o n t r o l s  w i t h 
dyslipidaemia, hypertensives with dyslipidaemia 
had higher mean values of total and LDL-
cholesterol though these differences were not 
statistically signicant as depicted in Table 5. 
In terms of lipid treatment status, out of the 32 
(53.3%) hypertensive patients with LDL-C 
>4.1mmol/L, only 8(25%) were on antilipid 
medication (Fig 2). Six (75%) patients were on 
statin alone while 2(25 %) were on a combination of 
niacin and statin.
DISCUSSION
The overall prevalence of dyslipidaemia among 
adult hypertensive patients in this study was 
44.0%. This gure is comparable to a prevalence 
4 
rate of 44.3% obtained in another study in 2012 in a 
South-Eastern Nigerian hospital, though the study 
was carried out among geriatrics. It is however 
5lower than the prevalence of 58.9%  obtained in 
South-West Nigeria and higher than the 
prevalence of 30.7% recorded in the 2004 study in 
19the United States  and 35% recorded in Turkish 
8 adults. The South-Western Nigeria study was 
c a r r i e d  o u t  a m o n g  n e w l y - d i a g n o s e d 
hypertensives and that may account for the 
differences. The lower prevalences seen in the 
western countries may be attributed to greater 
awareness among patients and consequently 
earlier presentation to health facilities, and earlier 
commencement of treatment. Other factors 
include, more inclusive health insurance cover, 
better access to healthcare and greater compliance 
to medication.
Among female patients, however, the prevalence 
of 47.0% of dyslipidaemia in hypertensive women 
seen in this study is consistent with the rate of 
20
49.5% recorded in the Genoa study  among black 
hypertensive females but is greater than 21% 
recorded among Turkish adult hypertensive 
8 
females. The 37.5% prevalence seen among 
hypertensive men also differed from 56.7% 
recorded in the Genoa study among black 
hypertensive males and 20% among Turkish adult 
hypertensive males. 
These gures buttress the fact that dyslipidaemia 
is commonly associated with hypertension hence 
increasing the risk of atherosclerosis and 
cardiovascular disease as each of them represents 
an independent major risk factor, and their co-
existence represents a synergism enhancing the 
development of atherosclerosis. However, the 
higher proportion of females with dyslipidaemia 
in the present study contrasts with documented 
ndings that men generally have higher 
 20, 21, 22
prevalence of dyslipidaemia than females.  
While this remains true, the higher proportion of 
females with dyslipidaemia in the present study 
may be due to the age of female participants most 
of who are in the menopausal age group. The mean 
menopausal age in Nigeria is documented to be 
2 3 2 4
49.4  and 46.16   years by two different 
researchers, and the mean age of female 
participants in the present study was 55.4 years 
which is quite higher than the documented age of 
menopause. Menopause has been reported to be 
2 5
associated with dyslipidaemia  and could 
therefore account for the ndings in this study.
In this study also, dyslipidaemia was found in 
23.0% of the healthy control group. Though this 
gure is lower than the 60% reported by 
26
Oguejiofor et al  in apparently healthy Nigerians, 
it is deemed high because it is higher than 
prevalences reported in some developed 
countries. Among Latin American populations, 
the prevalence of hypercholesterolaemia varied 
27
from 6% to 20%  depending on the city, and is 
28quoted as 22% in Australia.
This high prevalence of dyslipidaemia can partly 
be attributed to urbanization, western diet, and 
sedentary lifestyle.  Indeed, a report has 
demonstrated a higher prevalence in urban versus 
 29rural areas in Nigeria.
This elevated lipid levels in apparently healthy 
individuals is also worthy of note because 
dyslipidaemia alone is a major risk factor for 
development of atherosclerosis. More so, since it 
causes no symptoms, the individual remains 
ignorant of the condition and takes no precaution 
especially in a developing country like Nigeria  
where the culture of regular and routine medical 
evaluation is yet to be entrenched.
According to NCEP ATP recommendations, LDL-
c levels of >4.1 mmol/L in the presence of no 
Coronary Heart Disease and multiple (2 or more) 
13risk factors necessitates drug therapy.
In this study, hypertension, age (mean age of 56.5 
years), and 22% of dyslipidaemic patients with 
HDL-c < 1.0mmol/L are all coronary heart disease 
risk factors.
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The 75% of patients with multiple risk factors 
(hypertension, mean age of 56.5 years, abnormal 
lipid prole) who are not at goal and not on 
antilipids is worrisome as they are at increased risk 
of cardiovascular diseases. The nding of 25% 
dyslipidaemic drug-treated patients in this study 
is however higher than 16.4% and 12.8% reported 
respectively for black women and men in the 
 20
Genoa study.  
The 75% of patients (LDL-c >4.1 mmol/L) who are 
neither at goal nor on antilipids recorded in this 
30study is lower than the 80.3%  of patients with 
dyslipidemia who were either undiagnosed, un-
treated or under-treated recorded in Germany. 
This difference may be due to fact that the German 
study included not only hypertensive patients but 
all patients seen in the primary care setting.
The reasons for this poor treatment level in our 
study may not be unconnected with out-of-pocket 
nancing as national health insurance is yet to be 
all-encompassing and adequately utilized by 
patients. Others reasons may be low level of 
literacy among patients, poor patient compliance 
with medication and inadequate patient 
monitoring of lipid levels by clinicians.
STRENGHTS AND LIMITATIONS OF STUDY
Being a cross-sectional study, causality of the low 
lipid treatment level cannot be determined. Again, 
this study was conducted in one tertiary health 
fac i l i ty ,  hence  the  ndings  may not  be 
representative of the entire country of study. 
Hence, further research possibly a multi-center 
study in this area is needed. Despite these 
limitations, the present study contributes to the 
growing body of literature on dyslipidaemia in 
hypertension. It equally identies important gaps 
a n d  e x i s t i n g  m i s a l i g n m e n t  b e t w e e n 
internationally acknowledged treatment 
guidelines and practice of clinicians in the study 
location at the time of study. The current study can 
indeed provide support for further research in this 
area geared towards improved clinical care. 
CONCLUSION
High prevalence and poor treatment level of 
dyslipidaemic hypertension seen in this study 
requires prompt attention and concerted efforts 
from clinicians and other stakeholders in the 
health sector in order to reduce the risk of 
cardiovascular diseases among patients. There is a 
need to increase the awareness, both in the medical 
and patient communities, so that these two 
conditions can be adequately targeted and treated.
REFERENCES
1. Williams RR, Hunt SC, Hopkins PN, Stults BM, Wu 
LL, Hasstedt SJ, et al. Familial dyslipidemic 
hypertension: Evidence from 58 Utah families for a 
syndrome present in approximately 12% of 
patients with essential hypertension. JAMA 1988; 
259:3579-3586. 
2. Cominacini L, Rigoni A, Pasini AF, Garbin U, 
Davoli A, Campagnola M, et al. The binding of 
oxidized low density lipoprotein (ox-LDL) to ox-
LDL receptor-1 reduces the intracellular 
concentration of nitric oxide in endothelial cells 
through an increased production of superoxide. J 
Biol Chem.2001; 276(17):13750-1375. 
3. Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima 
S, Yokoyama M. Low concentration of oxidized 
l o w - d e n s i t y  l i p o p r o t e i n  a n d 
lysophosphatidylcholine upregulate constitutive 
nitric oxide synthase mRNA expression in bovine 
aortic endothelial cells. Circul Res. 1995; 76: 958-
962.
4. Iloh GUP, Amadi AN, Njoku PU, Ofoedu JN, Awa-
Madu J. The magnitude of abdominal adiposity 
and atherogenic dyslipidemia among geriatric 
Nigerians with arterial hypertension in a rural 
hospital in South-Eastern Nigeria. Niger J Clin 
Pract. 2012; 15: 462-468.
5. Akintude AA, Ayodele EO, Akinwusi OP, Opadijo 
GO. Dyslipidemia among newly diagnosed 
hypertensives: Pattern and Clinical Correlates. J 
Natl Med Assoc. 2010; 102:403-407.
6. Asaolu MF, Asaolu SS, Fakunle JB, Ogunleye ZA. 
Evaluation of lipid status of hypertensive 
Nigerians in Ado-Ekiti, western Nigeria. Der 
Pharmacia Lettre. 2010; 2(2):6-9.
7. Eaton B, Feldman A, Assaf R, McPhillips B, Hume 
L, Lasater M, et al. Prevalence of hypertension, 
dyslipidemia, and dyslipidemic hypertension. J 
Fam Pract. 1994; 38:17-23.
8. Onat A,  Toprak S,  Ceyhan K,  Sansoy V. 
Dyslipidemic Hypertension Among Turkish 
Adults. Arch Turk Soc Cardiol. 2002; 30:402-409.
9. W H O  G l o b a l  H e a l t h  O b s e r v a t o r y  d a t a 
www.who.int/gho/ncd/risk_factors/cholesterol
_text/en/ assessed on 7/5/2017.
10. Kadiri S, Control of cardiovascular disease in 
Africa, Bulletin of Medicus Mundi Switzerland 
2007;106.
222
Nigerian Journal of Medicine, Vol. 28  No. 3, July - September, 2019,  ISSN 1115-2613
11. Mensah GA, A heart-healthy and "stroke-free" 
world through policy development, systems 
change, and environmental supports: a 2020 vision 
for sub-Saharan Africa. Ethn Dis. 2003; 13(2 Suppl 
2):4-12.
12. JNC-8 Blood Pressure and ACC/AHA Cholesterol 
Guideline Updates. Ann Intern Med. 2014 doi: 
10.7326/M13-2981.
13. Grundy SM, Becker D, Clark LT, Cooper RS, Denke 
MA, Howard JW, et al. Third Report of the National 
Cholesterol Education Program (NCEP) Expert 
Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults (Adult 
Treatment Panel III): nal report. Circulation. 2002; 
106: 3143–3421.
14.  Goff Jr D.C,  Bertoni A.G, Kramer H, Bonds D, 
Roger S, BlumenthalR.S, et al. Dyslipidemia 
Prevalence, Treatment, and Control in the Multi-
Ethnic  Study of  Atherosclerosis  (MESA) 
Circulation. 2006; 113: 647-656.
15. Richmond W. Analytical reviews in clinical 
biochemistry; the quantitative analysis of 
cholesterol. Ann Clin Biochem. 1992; 29:577-597. 
16. Stein EA, Myers GL. National Cholesterol 
Education Program Recommendations for 
triglyceride measurement: executive summary. 
Clin Chem. 1995; 41:1421-1426.
17. Warnick GR, Nauck M, Rifai N. Evolution of 
methods for measurement of HDL-cholesterol: 
from ultracentrifugation to homogenous assays. 
Clin Chem. 2001: 47; 1579-1596.
18. Friedewald WT, Levy RI, Fredrickson DS. 
Estimation of the concentration of low-density 
lipoprotein cholesterol in plasma, without use of 
the preparative ultracentrifuge. Clin Chem. 1972; 
18: 499-502. 
19. Johnson ML, Pietz K, Battleman DS, Beyth RJ. 
Prevalence of co-morbidity hypertension and 
dyslipidemia and associated cardiovascular 
disease. Am J Manag Care. 2004; 10: 926-932.  
20. O'Meara JG, Kardia SL, Armon JJ, Brown CA, 
Boerwinkle E, Turner ST. Ethnic and sex 
differences in the prevalence, treatment, and 
control of dyslipidemia among hypertensive adults 
in the GENOA study. Arch Intern Med. 2004; 
164(12): 1313-1318.
21. Goff DC, Bertoni AG, Kramer H, Bonds D, 
Blumenthal RS, Tsai MY, et al. Dyslipidaemia 
prevalence, treatment and control in the Multi-
Ethnic Study of Atherosclerosis: Gender, Ethnicity 
and Coronary Artery Calcium. Circulation 
2006;113:647-56
22. Liu X, Yu S, Mao Z, Li Y, Zhang H, Yang K, et al. 
Dyslipidemia prevalence, awareness, treatment, 
control, and risk factors in Chinese rural 
population: the Henan rural cohort study. Lipids 
Health Dis. 2018;17(1):119
23. Ozumba BC, Obi SN, Obikili E, Waboso P. Age, 
Symptoms and Perception of Menopause among 
Nigerian women. J Obstet Gynecol Ind 2004; 
54(6):575 – 578
24. Achie LN, Olorunshola KV, Mabrouk M. Age at 
Natural Menopause among Nigerian Women in 
Zaria, Nigeria. Asian J. Med. Sci., 3(8): 151-153, 2011
25. Trishala A, Vishnu PV, Gayathiri R. Comparative 
assessment of lipid prole in pre and post-
menopausal women in Tuticorin district – a pilot 
study. Int J Pharm Bio Sci 2016; 7(3): 1109 - 1112
26. Oguejiofor OC , Onwukwe CH, Odenigbo CU. 
Dyslipidemia in Nigeria: prevalence and pattern. 
Ann Afr Med. 2012; 11(4):197-202.
27. Schargrodsky H, Hernandez-Hernandez R, 
Champagne BM, Silva H, Vinueza R, Silva 
Aycaguer LC et al. Assessment of cardiovascular 
risk in seven Latin American cities. Am J Med. 2008; 
121:58-65.
28. A u s t r a l i a n  B u r e a u  o f  S t a t i s t i c s  ( 2 0 0 6 ) . 
Cardiovascular disease in Australia: A snapshot, 
2004–05. Catalogue number 4821.0.55.00. Available 
from: http://www.abs.gov.au /ausstats/ 
abs@.nsf/ mf/4821.0.55.001
29. Glew RH, Conn CA, Vanderjagt TA, Calvin CD, 
Obadon MO, Crossey M et al. Risk factors for 
cardiovascular disease and diet of urban and rural 
dwellers in northern Nigeria. J Health Popul Nutr. 
2004; 22: 357–369. 
30. Böhler S, Scharnagl H, Freisinger F, Stojakovic T, 
Glaesmer H, Klotsche J,et al. Unmet needs in the 
diagnosis and treatment of dyslipidemia in the 
primary care setting in Germany. Atherosclerosis 
2007; 190(2):397-407.
223
Nigerian Journal of Medicine, Vol. 28  No. 3, July - September, 2019,  ISSN 1115-2613
